Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support.

[1]  S. Kelkar,et al.  Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure , 2019, JPEN. Journal of parenteral and enteral nutrition.

[2]  D. Seidner,et al.  Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. , 2017, Gastroenterology.

[3]  J. DiBaise,et al.  Managing the Adult Patient With Short Bowel Syndrome. , 2017, Gastroenterology & hepatology.

[4]  S. Kelkar,et al.  Impact of Teduglutide and Parenteral Nutrition (PN) Volume Reduction on Quality of Life (QoL) in Patients with Short Bowel Syndrome and PN Dependency , 2017 .

[5]  D. Teitelbaum,et al.  Outcomes from a 12‐Week, Open‐Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome , 2017, The Journal of pediatrics.

[6]  A. Van Gossum,et al.  ESPEN guidelines on chronic intestinal failure in adults. , 2016, Clinical nutrition.

[7]  S. O'keefe,et al.  Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome , 2016, Clinical and Translational Gastroenterology.

[8]  A. Forbes,et al.  Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study. , 2013, Clinical nutrition.

[9]  R. Gilroy,et al.  Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  M. Hiele,et al.  Epidemiology of catheter-related infections in adult patients receiving home parenteral nutrition: a systematic review. , 2013, Clinical nutrition.

[11]  P. Jeppesen.  Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome , 2012, Therapeutic advances in gastroenterology.

[12]  R. Gilroy,et al.  Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome , 2011, Gut.

[13]  L. Barbot,et al.  Tube feeding improves intestinal absorption in short bowel syndrome patients. , 2009, Gastroenterology.

[14]  J. Woodward,et al.  Guidelines for management of patients with a short bowel , 2006, Gut.

[15]  A. Buchman,et al.  Short bowel syndrome and intestinal failure: consensus definitions and overview. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  Morton B. Brown,et al.  Parenteral nutrition-associated cholestasis in neonates: multivariate analysis of the potential protective effect of taurine. , 2005, JPEN. Journal of parenteral and enteral nutrition.

[17]  M. Winkler.  Quality of life in adult home parenteral nutrition patients. , 2005, JPEN. Journal of parenteral and enteral nutrition.

[18]  A. Moore,et al.  Neonatal short bowel syndrome: a cohort study. , 2005, Journal of pediatric surgery.

[19]  M. Ament,et al.  Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: a 25-year experience. , 2004, The Journal of pediatrics.

[20]  C. Apovian,et al.  Nutritional Management of Short Bowel Syndrome in Adults , 2002, Journal of clinical gastroenterology.

[21]  T. Jaksic,et al.  Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. , 2001, The Journal of pediatrics.

[22]  J. Holst,et al.  Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon , 2000 .